Opinion of the Transparency Council – everolimus
At its meeting on 2 May 2025, the Transparency Council adopted opinion No. 71/2025 on the justification for transferring the active substance everolimus from drug program B.89. “Treatment with everolimus of patients with tuberous sclerosis with subependymal giant cell tumors (SEGA) ICD-10 Q85.1 not eligible for surgical treatment” to the catalog of drugs reimbursed in chemotherapy.